個案總覽

This short case discusses the process of Life Technologies' acquisition by Thermo Fisher in 2013 and 2014. The case is a complement to SM-209A and SM-209B, which highlight the various growth and acquisition strategies the company undertook over the previous 10 years.

On June 12, 2008, Invitrogen and Applied Biosystems announced plans to merge. The combined company was to be renamed Life Technologies (NASDAQ: LIFE). Invitrogen offered to acquire Applied Biosystems for $6.7 billion in cash and stock. AB shareholders would receive $38 per share in cash and stock, representing a 17 percent premium over the share's closing price on Wednesday, June 11, 2008.

Founded in 1987, Invitrogen was one of the largest catalog life science companies in the industry. Its customers came from academic research, biotechnology and pharmaceutical companies and government laboratories. Scientists viewed Invitrogen as a one-stop shop for all major molecular biology, biochemistry and cell culture reagent products, with prices ranging from a hundred dollars to a few thousand dollars.